← back to search

James Lindsay

Harvard University · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, and RNA modifications and cancer.
h-index
22
citations
4,894
works
461
NIH funding
primary concept
Medicine
email

Recent publications

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial
Clinical Cancer Research 2024cited by 41position: middledoi
Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal
Cancer Research 2023cited by 818position: middledoi
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial
˜The œLancet. Gastroenterology & hepatology 2023cited by 105position: middledoi
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Journal of Thoracic Oncology 2023cited by 41position: middledoi
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
JAMA Oncology 2022cited by 376position: middledoi
AACR Project GENIE: 100,000 Cases and Beyond
Cancer Discovery 2022cited by 104position: middledoi
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
Annals of Oncology 2022cited by 100position: middledoi
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
Annals of Oncology 2022cited by 32position: middledoi
Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis
Scientific Reports 2022cited by 20position: middledoi
SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition
Journal of Thoracic Oncology 2021cited by 148position: middledoi
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Clinical Cancer Research 2021cited by 101position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Thomas Yu · Western University of Health Sciences1 papers (2022–2022)Mizuki Nishino · Harvard University1 papers (2021–2021)Hersh Gupta · University of California, Los Angeles1 papers (2021–2021)Trevor J. Pugh · Ontario Institute for Cancer Research1 papers (2022–2022) · 1 papers (2022–2022)Marilyn M. Li · Affiliated Hospital of Guizhou Medical University1 papers (2022–2022)Brady Bernard · Cancer Institute (WIA)1 papers (2022–2022)Joao V. Alessi · Harvard University1 papers (2021–2021)Mark M. Awad · PCAS (France)1 papers (2021–2021)Michelle Green · LabCorp (United States)1 papers (2022–2022)Lynette M. Sholl · Harvard University1 papers (2021–2021)Jeffrey P. Bruce · Princess Margaret Cancer Centre1 papers (2022–2022)Michael L. Cheng · University of California, San Francisco1 papers (2021–2021)Tali Mazor · Dana-Farber Cancer Institute1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2022–2022)Bijaya Sharma · Dana-Farber Brigham Cancer Center1 papers (2021–2021)Kristen D. Felt · Dana-Farber Brigham Cancer Center1 papers (2021–2021)Biagio Ricciuti · Harvard University1 papers (2021–2021)Andrew D. Cherniack · Harvard University1 papers (2021–2021)